Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.

Song EY, Shin Y, Roh EY, Sue S, Park MH, Kim BH, Kim W, Yoon JH, Lee YJ, Park SJ, Jung EU, Lee JH, Myung SJ, Kim YJ, Lee HS

Journal of medical virology1 Jan 2011Cited by 9 (Europe PMC)

PMID21108343DOI10.1002/jmv.21961PepBankPUB-21108343

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneObservational studyOther
In HBeAg-positive chronic hepatitis B patients on peginterferon alpha-2a with or without thymosin alpha‑1, serum HBsAg correlated moderately with HBV DNA.
In plain wordsIn people with chronic hepatitis B on peginterferon with or without thymosin alpha‑1, two virus markers moved together moderately.
Peptide
Thymosin alpha-1
Outcome
Not applicableCorrelation of serum HBsAg with HBV DNA
Study
n = 37
Outcome group
Antiviral activity · Liver
Measurements
Correlation r
0.452
HBsAg vs HBV DNA
Source sentences
Summary
There was a moderate correlation between the HBsAg and HBV DNA levels (r = 0.452, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2110834301
02HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome
In patients on peginterferon alpha-2a with or without thymosin alpha‑1, median HBsAg fell from 6,218 IU/ml at baseline to 4,038 IU/ml at week 96.
In plain wordsIn people with hepatitis B on peginterferon, with or without thymosin alpha‑1, a virus marker fell from baseline to week 96.
Peptide
Thymosin alpha-1
Outcome
DecreaseMedian serum HBsAg at baseline and week 96
Study
n = 37
Outcome group
Antiviral activity · Liver
Measurements
Median HBsAg
6218 IU/ml
baseline
Median HBsAg
4038 IU/ml
week 96
Source sentences
Summary
Median HBsAg levels at baseline and at week 96 were 6,218 IU/ml and 4,038 IU/ml, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2110834302
03HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome
In patients on peginterferon alpha-2a with or without thymosin alpha‑1, mean HBV DNA fell from 7.48 to 5.37 log10 IU/ml at week 96.
In plain wordsIn people with hepatitis B on peginterferon, with or without thymosin alpha‑1, virus DNA levels fell by week 96.
Peptide
Thymosin alpha-1
Outcome
DecreaseMean HBV DNA at baseline and week 96
Study
n = 37
Outcome group
Antiviral activity · Liver
Measurements
Mean HBV DNA
7.48 log10 IU/ml
baseline
Mean HBV DNA
5.37 log10 IU/ml
week 96
Source sentences
Summary
The mean HBV DNA and alanine aminotransferase (ALT) levels were 7.48 log(10) IU/ml and 173 IU/L at baseline and 5.37 log(10) IU/ml and 102 IU/L at week 96, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2110834303
04HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome
In patients on peginterferon alpha-2a with or without thymosin alpha‑1, mean ALT fell from 173 to 102 IU/L at week 96.
In plain wordsIn people with hepatitis B on peginterferon, with or without thymosin alpha‑1, a liver enzyme level fell by week 96.
Peptide
Thymosin alpha-1
Outcome
DecreaseMean ALT at baseline and week 96
Study
n = 37
Outcome group
Liver fat and liver function · Liver
Measurements
Mean ALT
173 IU/L
baseline
Mean ALT
102 IU/L
week 96
Source sentences
Summary
The mean HBV DNA and alanine aminotransferase (ALT) levels were 7.48 log(10) IU/ml and 173 IU/L at baseline and 5.37 log(10) IU/ml and 102 IU/L at week 96, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2110834304
05HumanNot a test of Thymosin alpha-1 aloneObservational studyOther
In patients on peginterferon alpha-2a with or without thymosin alpha‑1, an HBsAg decrease to below 60% of baseline at week 12 independently predicted HBeAg seroconversion at week 96.
In plain wordsIn people with hepatitis B on peginterferon, with or without thymosin alpha‑1, an early drop in a virus marker predicted later response.
Peptide
Thymosin alpha-1
Outcome
Not applicableHBsAg decline to <60% of baseline at week 12 as predictor of HBeAg seroconversion
Study
n = 37
Outcome group
Antiviral activity · Liver
Measurements
Odds ratio
45.7
HBeAg seroconversion at week 96
Source sentences
Summary
A decrease to <60% of baseline levels of HBsAg at week 12 was identified as an independent predictive factor for HBeAg seroconversion (OR = 45.7, P < 0.05) at week 96.
1 context sentence(design, population, supporting numbers)
Summary · context
Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2110834305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.

Summary

Results from this study5

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

MeSH terms